Historical AI Consensus
This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.
- Symbol
- REL.LSE
- Batch
- 7
- Published
- September 20, 2026
- AI Advisors
- 14
Historical AI Consensus Investment Thesis
Relx (REL) Stock Forecast and AI Rating
Forecast targets and rating
Published batch rating
STRONG BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
STRONG BUY2,891 GBX
+15.7%+17.8% incl. dividends5-Year
STRONG BUY4,568 GBX
+82.8%+99.9% incl. dividendsPublished batch insight
Enterprise Information Moats Defeat Artificial Intelligence Commoditization Fears Through Cash Compounding
High consensus confirms that proprietary legal, risk, and scientific datasets protect the business from artificial intelligence disintermediation, driving steady high-single-digit cash compounding and disciplined share buybacks, while elevated sovereign interest rates and open-access publishing pressures remain the decisive frictions.
This analysis preserves the original published batch. Audit published forecasts in full transparency
Elon Musk (Visionary), Superintelligence (Anthropologist), Universal Investor (Polymath), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower), Warren Buffett (Value Purist), Michael Burry (Vulture), Ray Dalio (Strategist), Machiavelli (Insider). Some archetypes run in multiple modes, resulting in 14 advisors total.
Full published thesis
Executive Summary
If you invested $10,000 in Relx at the forecast anchor (2026-09-18): $19,729 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 1.8% net dividend yield for Relx.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in GBX; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (GBX) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 2,597.56 | +3.94% | +3.94% | Autumn trading updates confirm resilient legal and risk subscription renewals, while active share repurchases absorb secondary market supply. High sovereign bond yields cap immediate multiple expansion, generating a measured advance driven primarily by cash returns. |
| Q1 2027 | 2,728.89 | +5.06% | +9.20% | Full-year results confirm underlying revenue growth near seven percent alongside operating margin expansion. Proof of durable contract values despite generative tool availability eases terminal disruption fears, prompting initial valuation multiple recovery and short covering. |
| Q2 2027 | 2,817.65 | +3.25% | +12.75% | Spring contract renewals demonstrate steady adoption of premium AI-integrated workflows across law firms. Persistent sterling strength against the dollar creates a modest translation friction, tempering headline gains while underlying per-share cash compounding remains intact. |
| Q3 2027 | 2,890.59 | +2.59% | +15.67% | Interim reporting highlights accelerating underlying growth in legal workflows and resilient fraud verification volumes. Demonstrating that integrated tools expand contract values rather than cannibalizing seats supports another leg of earnings-led share price appreciation. |
| Q4 2027 | 2,995.14 | +3.62% | +19.85% | Year-end enterprise budget deployments favor non-discretionary regulatory compliance and fraud prevention platforms. Investors rotate capital toward high-conversion cash generators, providing defensive valuation support as broader European macroeconomic indicators show late-cycle cooling. |
| Q1 2028 | 3,127.54 | +4.42% | +25.15% | Annual disclosures validate sustained operating cash conversion near ninety-eight percent alongside a refreshed share buyback authorization. Management's capital allocation discipline and consistent operating profit growth convince institutional capital to re-anchor forward valuation multiples higher. |
| Q2 2028 | 3,190.09 | +2.00% | +27.65% | Competitive legal software discounting and rising amortisation from earlier product development create temporary margin scrutiny. A mild valuation consolidation occurs as investors reassess medium-term terminal growth expectations across professional information services. |
| Q3 2028 | 3,290.56 | +3.15% | +31.68% | Interim figures demonstrate that non-cyclical risk analytics demand and scientific decision tools offset localized software pricing friction. Robust transaction volumes across identity verification platforms reaffirm franchise quality, enabling a steady resumption of the upward trend. |
| Q4 2028 | 3,389.59 | +3.01% | +35.64% | Cross-border compliance enforcement drives strong year-end enterprise contract renewals. Stabilizing benchmark bond yields reduce long-duration equity discount rates, allowing steady share count reduction to translate directly into solid per-share equity gains. |
| Q1 2029 | 3,524.85 | +3.99% | +41.05% | Fiscal results confirm that multi-year equity retirement has shrunk the share float substantially, boosting per-share cash metrics. Improved balance-sheet flexibility reduces credit risk premiums, prompting institutional growth funds to accumulate positions steadily. |
| Q2 2029 | 3,595.02 | +1.99% | +43.86% | Academic library consortium negotiations and open-access mandates restrict pricing flexibility within scientific publishing. However, expansion in healthcare clinical solutions and digital tools offsets publishing headwinds, preserving modest positive period progress. |
| Q3 2029 | 3,706.57 | +3.10% | +48.32% | Risk solutions captures expanding transaction volume from financial institutions combating sophisticated digital identity fraud. Incremental revenues flow through to operating profit at high contribution margins, widening the group operational spread and lifting valuation. |
| Q4 2029 | 3,772.04 | +1.77% | +50.94% | Higher corporate refinancing costs and periodic corporate travel pauses in exhibitions prompt cautious sentiment. Shares experience minor technical consolidation as the market digests prior gains and awaits audited confirmation of annual cash conversion. |
| Q1 2030 | 3,911.29 | +3.69% | +56.51% | Full-year reporting confirms underlying operating profit growth outrunning top-line revenue, validating structural operational leverage. Progressive dividend increases combined with uninterrupted buyback execution reassure income-focused allocators, driving steady share price appreciation. |
| Q2 2030 | 4,016.56 | +2.69% | +60.73% | Clinical analytics and automated legal reasoning tools achieve broad penetration across established enterprise accounts. Switching costs remain prohibitive due to regulatory compliance standards, securing predictable subscription renewals and sustaining firm valuation levels. |
| Q3 2030 | 4,124.67 | +2.69% | +65.05% | Interim reporting confirms that mature AI-enabled software cohorts deliver robust returns on capital. Stable customer retention across corporate legal departments and insurance carriers preserves cash generation, supporting measured earnings-led upward momentum. |
| Q4 2030 | 4,225.67 | +2.45% | +69.09% | Late-cycle macroeconomic conditions prompt general enterprise cost scrutiny, yet non-discretionary risk and compliance subscriptions remain fully insulated. Continuous equity retirements provide persistent technical support to per-share valuations heading into year-end. |
| Q1 2031 | 4,366.26 | +3.33% | +74.72% | Annual financial results demonstrate that long-term digital mix shifts have cemented operating margins near thirty-six percent. The market fully prices the business as a durable decision infrastructure asset, rewarding sustained capital discipline. |
| Q2 2031 | 4,466.64 | +2.30% | +78.74% | Mature subscription markets face slight pricing discipline from competing software agents, keeping revenue gains modest. High cash conversion and disciplined balance-sheet management ensure predictable dividend and capital return delivery. |
| Q3 2031 | 4,568.50 | +2.28% | +82.81% | The terminal forecast window closes with valuation multiples anchored near twenty times forward earnings. Five years of steady operational compounding and significant float contraction complete a resilient, cash-funded investment cycle. |
The prevailing thesis treats professional information providers as vulnerable to disintermediation by generative artificial intelligence, pricing in structural terminal multiple compression. Forensic analysis of operating reality decisively refutes this assumption. Enterprise customers in legal, healthcare, and underwriting sectors do not purchase generic text synthesis; they procure indemnified, legally admissible citations and contributory fraud telemetry where error tolerance is zero. Far from eroding demand, embedded domain models accelerate contract values, driving underlying revenue expansion of seven percent and expanding adjusted operating margins toward thirty-six percent. Valuation sensitivity remains tied to high global benchmark yields and capital allocation execution rather than technology obsolescence. The genuine constraint is balance-sheet optimization: net debt of two point three times EBITDA limits debt-funded distributions, requiring repurchases to be funded purely from free cash flow.
Key insights
- Embedded proprietary citation graphs convert artificial intelligence into an average revenue per user expander rather than a seat-destroying substitute across institutional clients.
- Systematic capital return programs mechanically retire two to four percent of equity annually, driving per-share compounding well ahead of top-line revenue.
- Reconciled accounts show forward multiples near eighteen times, proving the investment thesis relies on durable cash compounding rather than extreme re-rating.
Investors recently worried that new artificial intelligence tools would replace established professional data companies, pushing share prices down. In reality, lawyers, doctors, and banks cannot afford artificial intelligence errors or made-up facts. They depend on verified court records, medical research, and fraud registries to do their jobs safely. The company embeds smart digital tools directly into its existing platforms, allowing it to charge higher subscription rates while keeping renewal rates remarkably high.
Key insights
- Verified legal, medical, and fraud records cannot be legally duplicated by generic artificial intelligence tools.
- Excellent cash conversion allows management to buy back shares consistently, boosting per-share earnings value each year.
- Strong customer retention and multi-year subscription contracts protect company profits against broader economic slowdowns.
Deep Dive
Prevailing market consensus treats the business as an endangered legacy publisher vulnerable to terminal disruption from generative artificial intelligence models. Investors and sell-side analysts anchor on early 2026 software drawdowns, assuming open reasoning tools will commoditize proprietary legal search and academic paywalls. Consequently, positioning reflects skepticism, pricing in permanent multiple compression while overlooking accelerating underlying software revenues and resilient subscription renewal rates across all core operating divisions.